Li Chen – Founder, Executive Director, CEO and CSO, Hua Medicine, China

While others have failed during the last 30 years, Hua Medicine has finally succeeded in developing a breakthrough diabetes treatment controlling blood glucose levels by taking a novel approach and modulating the glucokinase enzyme. The company is now applying the same principles to develop treatments for CNS disorders. Hua Medicine’s CEO, Dr Li Chen, explains his innovative approach to drug development based on his background in laboratory automation and drug discovery, the synergies between the new drug and existing treatments, and lays out his ambition to get his first-in-class treatment to all the diabetes patients around the world who desperately need it.  
For me, it was the best time to set up a company like Hua Medicine. The environment was ripe to leverage global innovation, China’s expertise, the fast-growing technology platforms in order to develop a truly innovative drug in China
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report